Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Following the emergence of a novel coronavirus 1 (SARS-CoV-2) and its spread outside of China, Europe has experienced large epidemics. In response, many European countries have implemented unprecedented non-pharmaceutical interventions such as closure of schools and national lockdowns. We study the impact of major interventions across 11 European countries for the period from the start of COVID-19 until the 4 th of May 2020 when lockdowns started to be lifted. Our model calculates backwards from observed deaths to estimate transmission that occurred several weeks prior, allowing for the time lag between infection and death. We use partial pooling of information between countries with both individual and shared effects on the reproduction number. Pooling allows more information to be used, helps overcome data idiosyncrasies, and enables more timely estimates. Our model relies on fixed estimates of some epidemiological parameters such as the infection fatality rate, does not include importation or subnational variation and assumes that changes in the reproduction number are an immediate response to interventions rather than gradual changes in behavior. Amidst the ongoing pandemic, we rely on death data that is incomplete, with systematic biases in reporting, and subject to future consolidation. We estimate that, for all the countries we consider, current interventions have been sufficient to drive the reproduction number $${R}_{t}$$ R t below 1 (probability $${R}_{t}\,$$ R t < 1.0 is 99.9%) and achieve epidemic control. We estimate that, across all 11 countries, between 12 and 15 million individuals have been infected with SARS-CoV-2 up to 4 th May, representing between 3.2% and 4.0% of the population. Our results show that major non-pharmaceutical interventions and lockdown in particular have had a large effect on reducing transmission. Continued intervention should be considered to keep transmission of SARS-CoV-2 under control.

[1]  Andrew Gelman,et al.  Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .

[2]  Joshua B. Plotkin,et al.  Reconstructing influenza incidence by deconvolution of daily mortality time series , 2009, Proceedings of the National Academy of Sciences.

[3]  Joel C. Miller,et al.  A Note on the Derivation of Epidemic Final Sizes , 2012, Bulletin of mathematical biology.

[4]  Jérôme Hugues,et al.  Model‐Based Analysis , 2013 .

[5]  C. Fraser,et al.  A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics , 2013, American journal of epidemiology.

[6]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[7]  S. Lai,et al.  Patterns of human social contact and contact with animals in Shanghai, China , 2019, Scientific Reports.

[8]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[9]  J. Van Wyk,et al.  Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys , 2020, medRxiv.

[10]  Cécile Viboud,et al.  Age profile of susceptibility, mixing, and social distancing shape the dynamics of the novel coronavirus disease 2019 outbreak in China , 2020, medRxiv.

[11]  Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute , 2020 .

[12]  A. Hyafil,et al.  Analysis of the impact of lockdown on the reproduction number of the SARS-Cov-2 in Spain , 2020, Gaceta sanitaria.

[13]  Yongsheng Wu,et al.  Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study , 2020, The Lancet Infectious Diseases.

[14]  Carl A. B. Pearson,et al.  Inferring the number of COVID-19 cases from recently reported deaths , 2020, Wellcome open research.

[15]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.

[16]  C. Whittaker,et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.

[17]  A. Hyafil,et al.  Analysis of the impact of lockdown on the evolution Covid-19 epidemics in Spain , 2020, medRxiv.

[18]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[19]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[20]  N. G. Davies,et al.  The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study , 2020, medRxiv.

[21]  N. G. Davies,et al.  Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study , 2020, The Lancet Public Health.

[22]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[23]  H. Ullum,et al.  Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.